HL-60, IL-8 release (PMA stimulation)HL60-0001
Macrophage-like HL-60 (vit. D3/TGF- beta-differentiated)
ELISA / EIA
PMA (0,1 µg/ml)
Blood and lymphatic system, cardiovascular system and immunity > Immuno-inflammation assays using blood/immune cells > Monocytes/macrophages
Our sales team is here to help you find solutions:
- Technical feasibility study of your project
- Development of an assay selection strategy
- Definition of an experimental scheme
- Financial assessment and contractual agreements (costs, turnaround time, non-disclosure agreements, etc.)
Price: our pricing system consists of a fixed price per study + pricing per unit (price per replicate or experimental condition)
Start of assays and turnaround time: the start of an assay is subject to the receipt of your agreement and of the compounds to be tested. The sending date of the study report is communicated by email when the study starts. Although of an average of 5 to 10 weeks, our turnaround time may be subject to some fluctuation (due to availability of biological samples, to workload, etc.).
Required quantity of compounds: the required quantity is generally of a few mg or ml but may vary according to the form and solubility of compounds and to the concentrations to be tested. Please contact us for an estimation.
Customized protocols: for this assay, as for all of our assays, we can develop a protocol adapted to your needs. Should you have any question, please contact us.
Validation: the assays listed in the catalogue have undergone a preliminary validation and are subject to Standard Operating Procedures (SOPs) and to validation criteria. However, the robustness of each assay may be different according to the models and to the analytical methods. Please do not hesitate to contact us for more information.
Report and experimental data: our services include the writing of a study report in English or in French. This scientific report is provided in a PDF or Microsoft® Office format.
Laboratory / Location: this assay (as all of our assays) will be carried out in our Gençay laboratory in France.
|PBMC-0042||PBMC, M2-type macrophage induction in a MLR (Mix Lymphocyte Reaction) culture (basal)||*** (must be login)||*** (must be login)|
|PBMC_Lb-0002||PBMC, arachidonic acid metabolite release (A23187 stimulation)||*** (must be login)||*** (must be login)|
|THP1-0007||THP-1, IL-1 beta release (LPS stimulation)||*** (must be login)||*** (must be login)|
|MONO-0004||Monocytes, opioid receptor labeling (Basal)||ChemR23 expression|
delta-opioid receptor (DOR) expression
Delta-type opioid receptor 1 (OPRD1) expression
mu -opioid receptor (MOR) expression
|MONO-0009||CD14+ monocytes, Cytokine release (basal)||IL-1 beta, IL-6, IL-8, TNF- alpha release||Flow cytometry (multiplex)|
|MONO-0014||Activated M2 macrophages, Switch towards M1 macrophages (basal)||CD80 and CD163 phenotyping and cell viability (TOPRO-3)|
TNF- alpha, IL-6, IL-12p70 release
|MONO-0013||CD14+ monocytes, M2-type polarized macrophages, Phenotyping and cell viability (basal)||CD80 and CD163 phenotyping and cell viability (TOPRO-3)||Flow cytometry|
|MONO-0007||M1 macrophages, Phenotyping and/or Cytokine release (IFN- gamma + LPS stimulation)||CD80 and CD163 phenotyping and cell viability (TOPRO-3)|
TNF- alpha, IL1 beta, IL-6, IL-10, IL12p70 release
|Flow cytometry (multiplex)|
|MONO-0011||CD14+ monocytes, M1-type polarized macrophages, Phenotyping and cell viability (basal)||CD80 and CD163 phenotyping and cell viability (TOPRO-3)||Flow cytometry|
|PBMC-0038||PBMC, inflammation gene expression (LPS stimulation)||qPCRarray (16 genes)||qPCRarray (standard or customized)|